

July 25, 2024

Corporate Relationship Department
BSE Limited,
PJ Towers, Dalal Street,
Mumbai- 400001

Dear Sirs

Sub: Outcome of the Board meeting- Unaudited Financial Results and Limited Review Report for the quarter ended June 30, 2024

**Ref: 1) Regulation 33 of SEBI (LODR) Regulations, 2015
2) Script Code: 526783**

In terms of Regulation 30, 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”), we wish to inform that the Board of Directors of the company at its meeting held today i.e., on July 25, 2024, commenced at 11.00 A.M and concluded at 12 Noon have inter alia transacted the following businesses:

- 1) Approved the Un-Audited Financial Results of the Company for the quarter ended June 30, 2024. Copies of the Un-Audited Financial Results and Limited Review Report issued by the Statutory Auditors of the company for the said quarter is enclosed.
- 2) The Company has made arrangement for release of the Un-Audited Financial Results for the quarter ended June 30, 2024 in the newspaper as per the requirement of the LODR Regulations.
- 3) The Committees of the Board of Directors of the Company have been reconstituted as under:

Audit Committee:

Name of the Director	DIN	Designation
Mr. Sanjay Anand	02501139	Chairman
Dr. Amar Agarwal	00435684	Member
Ms. Latha Ramanathan	07099052	Member
Mr. Balakrishnan Venkatraman	02825465	Member

Stakeholders Relationship Committee:

Name of the Director	DIN	Designation
Mr. Sanjay Anand	02501139	Chairman
Dr. Amar Agarwal	00435684	Member
Ms. Latha Ramanathan	07099052	Member
Mr. Balakrishnan Venkatraman	02825465	Member



Nomination and Remuneration Committee:

Name of the Director	DIN	Designation
Mr. Sanjay Anand	02501139	Chairman
Dr. Adil Agarwal	01074272	Member
Ms. Latha Ramanathan	07099052	Member

Corporate Social Responsibility Committee:

Name of the Director	DIN	Designation
Dr. Athiya Agarwal	01365659	Chairman
Mr. Sanjay Anand	02501139	Member
Dr. Amar Agarwal	00435684	Member
Ms. Latha Ramanathan	07099052	Member

Kindly take the above information on record.

Thanking you,

Yours sincerely,

For **Dr. Agarwal's Eye Hospital Limited**

Meenaskshi Jayaraman
Company Secretary and Compliance Officer

Encl: a/a



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter ended 30 June 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Firm's Registration No. 008072S)



R. Prasanna Venkatesh

R. Prasanna Venkatesh
(Partner)
(Membership No.214045)

Place: Chennai
Date: 25 July 2024
UDIN: 24214045BKELC4939

Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com



(Amount in INR Crores except EPS)


Statement of Unaudited Financial Results for the Quarter Ended 30th June 2024

S.No.	Particulars	Quarter Ended			Year ended
		30-Jun-24 (Unaudited)	31-Mar-24 (Refer Note 3)	30-Jun-23 (Unaudited)	31-Mar-24 (Audited)
1	Income				
	(a) Revenue from Operations	100.02	80.72	78.55	319.30
	(b) Other Income	0.40	2.46	0.36	4.97
	Total Income	100.42	83.18	78.91	324.27
2	Expenses				
	(a) Purchase of Stock-in-Trade	11.56	8.85	8.49	35.95
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(1.41)	(0.56)	(0.63)	(2.25)
	(c) Surgical Lens including other consumables	11.89	9.01	8.57	36.85
	(d) Consultancy Charges for Doctors	14.24	11.72	11.21	48.37
	(e) Employee Benefit Expenses	17.57	15.41	16.43	63.78
	(f) Finance Costs	3.03	2.03	1.62	7.17
	(g) Depreciation and Amortisation Expense	9.87	7.53	5.85	26.61
	(h) Other Expenses	14.76	11.85	11.83	45.54
	Total Expenses	81.51	65.84	63.37	262.02
3	Profit before tax (1-2)	18.91	17.34	15.54	62.25
4	Tax Expense				
	- Current Tax	5.21	4.70	4.17	16.22
	- Deferred Tax (Net)	(0.41)	(0.15)	(0.17)	(0.33)
5	Net Profit after tax for the period (3-4)	14.11	12.79	11.54	46.36
6	Other Comprehensive Income				
	(a) Items that will not be reclassified to the Statement of Profit and Loss				
	- Actuarial (loss) / gain on defined benefit obligation	0.03	1.03	(0.12)	0.05
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	(0.01)	(0.27)	0.03	(0.01)
	Total Other Comprehensive income / (loss) (net of tax)	0.02	0.76	(0.09)	0.04
7	Total Comprehensive Income / (Loss) (5+6)	14.13	13.55	11.45	46.40
8	Paid-up equity share capital (Face value INR 10/- each)	4.70	4.70	4.70	4.70
9	Reserves (Other Equity)				152.45
10	Earnings Per Equity Share (EPS) (Face value of INR 10/- each)				
	(a) Basic	30.02	27.21	24.55	98.64
	(b) Diluted	30.02	27.21	24.55	98.64
		(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

- The above unaudited financial results have been prepared in accordance with the Indian Accounting Standard ('Ind AS') notified under Section 133 of the Companies Act, 2013, read together with the Companies (Indian Accounting Standards) Rules, 2013 (as amended).
- The above unaudited financial results have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors in their meeting held on 25th July 2024. The above results for the quarter ended 30th June 2024 has also been subjected to limited review by Statutory Auditors of the Company.
- The figures for the quarter ended 31st March 2024 are the balance figures between the audited figures for the year ended 31st March 2024 and the unaudited year to date figures for the nine months ended 31st December 2023, which were subjected to limited review by the Statutory Auditors.
- The Company operates in a single segment i.e. "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- During the current quarter, the Company has entered into a Business Transfer Agreement for acquisition of an eye hospital in Chennai for a total consideration of INR 27 Crores. The Company has accounted for the same in accordance with Ind As 103 on a provisional basis as at 30th June 2024.
- Figures for the previous periods, wherever necessary, have been regrouped/reclassified to conform to the current period's presentation.

Place : Chennai
Date : 25th July 2024



By order of the Board

Dr. Amar Agarwal
Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter ended 30th June 2024

Particulars	Quarter Ended			Year ended
	30-Jun-24 (Unaudited)	31-Mar-24 (Refer Note 2)	30-Jun-23 (Unaudited)	31-Mar-24 Audited
Revenue from Operations	100.02	80.72	78.55	319.30
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	18.91	17.34	15.54	62.25
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	18.91	17.34	15.54	62.25
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	14.11	12.79	11.54	46.36
Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	14.13	13.55	11.45	46.40
Paid-up Equity Share Capital (Face Value of INR 10/- each)	4.70	4.70	4.70	4.70
Reserves (Other Equity)				152.45
Earnings Per Share (for continuing and discontinued operations) (Face Value of INR 10/- each):				
(a) Basic	30.02	27.21	24.55	98.64
(b) Diluted	30.02	27.21	24.55	98.64
	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

- 1) The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).
- 2) The figures for the quarter ended 31st March 2024 are the balance figures between the audited figures for the year ended 31st March 2024 and the unaudited figures for the nine months ended 31st December 2023, which were subjected to limited review by Statutory Auditors.
- 3) Figures for the previous periods, wherever necessary, have been regrouped/reclassified to conform to the current period's presentation.

By order of the Board



Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684

Place : Chennai
Date : 25th July 2024